文献速递特殊人群用药药物不良反应与药物警戒

恩格列净治疗儿童糖原贮积病Ib型中性粒细胞减少的系统评价与Meta分析

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta-analysis.
PubMed 文献 · Br J Clin Pharmacol · 2025-09-30

该系统评价与Meta分析纳入6项非随机研究共177例儿童GSD-Ib患者,评估恩格列净对中性粒细胞减少的疗效与安全性。所有研究均报告恩格列净治疗后中性粒细胞计数改善(ANC>1.5),4项研究中性粒细胞减少缓解率>80%且均显示G-CSF减量或停用,不良事件轻微,乳酸酸中毒最严重。但多数研究存在严重或极严重偏倚风险,结论需谨慎解读。

要点

  • 恩格列净可改善儿童GSD-Ib患者中性粒细胞计数并减少G-CSF使用。
  • 不良事件少,乳酸酸中毒为最严重不良事件。
  • 证据多来自非随机研究且偏倚风险高,结论仅为初步。

核心结论

  • 恩格列净在儿童GSD-Ib中性粒细胞减少治疗中显示出有希望的疗效与安全性,但证据受研究设计和异质性限制,应视为初步结论。

研究设计与样本

  • 遵循2020 PRISMA指南的系统评价与Meta分析,检索PubMed、Embase和Web of Science(2015-2025年),末次检索2025年5月16日。
  • 纳入患者<18岁、GSD-Ib伴中性粒细胞减少且接受恩格列净治疗的研究,研究类型包括随机对照试验、观察性研究和病例系列。
  • 共纳入6项非随机研究,n=177,52%为男性,平均年龄6.7岁。
  • 采用ROBINS-I V2评估偏倚风险,GRADE评估证据确定性,Meta分析根据异质性选择固定或随机效应模型。

主要发现

  • 所有研究报告恩格列净治疗后中性粒细胞计数改善(ANC>1.5)。
  • 4项研究中性粒细胞减少缓解率>80%,所有研究均显示G-CSF减量或停用。
  • 不良事件轻微,乳酸酸中毒为最严重的不良事件。
  • 两项研究偏倚风险低,三项研究存在极严重偏倚风险。

关键数值与推荐

  • 主要疗效结局定义为中性粒细胞减少的缓解,安全性结局包括总体不良事件。
  • 纳入标准:患者<18岁、GSD-Ib伴中性粒细胞减少、接受恩格列净治疗;排除非英文、2015年前发表及非原始研究。

临床怎么用

  • 恩格列净可作为儿童GSD-Ib中性粒细胞减少的潜在治疗选择,尤其用于减少G-CSF用量。
  • 临床使用时需监测中性粒细胞计数和G-CSF需求变化,并警惕乳酸酸中毒等不良事件。
  • 因证据等级有限,治疗决策应结合患者具体情况并谨慎评估获益与风险。

局限性

  • 多数纳入研究为非随机设计,根据ROBINS-I工具评为严重或极严重偏倚风险,显著限制汇总结果的可靠性和可解释性。
  • 研究间存在异质性,结果应视为初步结论并谨慎解读。
  • 需要进一步随机试验,特别是测量1,5-AG的试验,以确认恩格列净作为G-CSF有希望疗法的角色。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Glycogen storage disease type Ib (GSD-Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G-CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option. This systematic review and meta-analysis assess its feasibility, efficacy and safety in paediatric GSD-Ib patients. METHODS: Following the 2020 PRISMA guidelines, a systematic search was conducted in PubMed, Embase and Web of Science (2015-2025). The last search was performed on 16 May 2025. The inclusion criteria were patients <18 years with GSD-Ib and neutropenia treated with empagliflozin. Eligible study types included randomized controlled trials (RCTs), observational studies and case series. Non-English, pre-2015 and non-primary research were excluded. Bias was assessed using ROBINS-I V2, and certainty via GRADE. Meta-analyses used fixed or random effects depending on heterogeneity. The primary efficacy outcome was defined as resolution of neutropenia, and safety outcome included overall adverse events. RESULTS: Six non-randomized studies (n = 177; 52% male; mean age 6.7) met the inclusion criteria. Two studies showed low risk of bias; three were critically biased. All reported improved neutrophil counts (ANC > 1.5) after empagliflozin treatment. Four studies had >80% resolution of neutropenia; all showed G-CSF reduction or discontinuation. Adverse events were minimal; lactic acidosis was the most serious. CONCLUSIONS: Empagliflozin shows promise in treating neutropenia in paediatric GSD-Ib patients, with encouraging efficacy and safety. However, findings are limited by study design and heterogeneity. The majority of included studies were non-randomized and rated as having a serious or critical risk of bias according to the ROBINS-I tool. This substantially limits the reliability and interpretability of pooled outcomes. These results should therefore be viewed as preliminary and interpreted with caution. Further randomized trials, especially those measuring 1,5-AG, are needed to confirm empagliflozin's role as promising therapy in G-CSF.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Iwasyk E, Jin R, Tuzzolino F, et al. Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta-analysis. Br J Clin Pharmacol. 2025. PMID: 41024628. doi:10.1002/bcp.70294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。